Trial Profile
Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients With Congenital Haemophilia and Inhibitors
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Vatreptacog alfa (Primary) ; Eptacog alfa
- Indications Haemophilia
- Focus Therapeutic Use
- Acronyms adept2
- Sponsors Novo Nordisk
- 12 Sep 2015 Results (post hoc analysis) published in the Journal of Thrombosis and Haemostasis.
- 19 May 2014 New trial record